We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Read MoreHide Full Article
Key Takeaways
Doximity's Q1 adjusted EPS was 36 cents, exceeding the Zacks Consensus Estimate by 16.1%.
Doximity's revenues grew 15.2% year over year to $145.9 million, driven by subscription gains.
DOCS raised its full-year revenue outlook to $628 million to $636 million from $619 million to $631 million.
Doximity, Inc. (DOCS - Free Report) delivered adjusted earnings per share (EPS) of 36 cents in the first quarter of fiscal 2026, which increased 28.6% year over year. The figure surpassed the Zacks Consensus Estimate by 16.1%.
GAAP EPS for the quarter was 27 cents, reflecting an uptick of 28.6% from the year-ago figure.
DOCS’ Revenues in Detail
Doximity registered revenues of $145.9 million in the fiscal first quarter, up 15.2% year over year. The figure surpassed the Zacks Consensus Estimate by 4.5%.
Shares of this company gained nearly 7.7% in today’s pre-market trading.
Doximity’s Segment Details
Doximity derives revenues from two sources: Subscription and Other.
In the first quarter of fiscal 2026, the Subscription revenues totaled $137.9 million, up 14.9% year over year. This was driven by the addition of new subscription customers and the expansion of existing customers. The expansion of existing customers was primarily driven by average revenue per existing Marketing Solutions customers increasing 14% as a result of adding new and growing existing brands and service lines.
The Other revenues totaled $8 million, up 19.8% year over year.
In the quarter under review, Doximity’s gross profit rose 15% year over year to $130.1 million. However, the gross margin contracted 13 basis points (bps) to 89.2%.
Sales and marketing expenses increased 3.2% year over year to $36.4 million, while research and development expenses increased 18.7% year over year to $26.8 million. General and administrative expenses increased 34.4% year over year to $12.4 million. Total operating expenses of $75.6 million rose 12.7% year over year.
The operating profit totaled $54.5 million, reflecting an 18.4% uptick from the prior-year quarter. The operating margin in the fiscal first quarter expanded 101 bps to 37.4%.
Doximity’s Financial Position
Doximity exited first-quarter fiscal 2026 with cash and cash equivalents of $137.3 million compared with $209.6 million at fiscal 2025-end.
Net cash provided by operating activities at the end of first-quarter fiscal 2026 was $62.1 million compared with $41.2 million a year ago.
DOCS’ Guidance
Doximity has provided its financial outlook for the second quarter of fiscal 2026 and upped its outlook for the full fiscal year.
For the fiscal second quarter, the company expects revenues in the range of $157 million-$158 million. The Zacks Consensus Estimate is pegged at $150.4 million.
DOCS now projects its full fiscal year revenues between $628 million and $636 million, up from the prior outlook of $619 million and $631 million. The Zacks Consensus Estimate is pegged at $625.7 million.
Our Take on Doximity
Doximity exited the first quarter of fiscal 2026 with better-than-expected results and solid top and bottom-line results. Robust performances by both its revenue sources were encouraging. The operating margin expansion also bodes well.
On the earnings call, management shared a few updates about its performance during the quarter. Per them, the unique active users on a quarterly, monthly and daily basis all grew in double-digit percentages year over year, while a record number of unique active prescribers used Doximity’s workflow tools to provide better care for their patients. The company also recently launched Doximity AI scribe. These look promising for the stock.
However, the gross margin contraction during the quarter was disappointing.
DOCS’ Zacks Rank and Key Picks
Doximity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. (GEHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Key Takeaways
Doximity, Inc. (DOCS - Free Report) delivered adjusted earnings per share (EPS) of 36 cents in the first quarter of fiscal 2026, which increased 28.6% year over year. The figure surpassed the Zacks Consensus Estimate by 16.1%.
GAAP EPS for the quarter was 27 cents, reflecting an uptick of 28.6% from the year-ago figure.
DOCS’ Revenues in Detail
Doximity registered revenues of $145.9 million in the fiscal first quarter, up 15.2% year over year. The figure surpassed the Zacks Consensus Estimate by 4.5%.
Shares of this company gained nearly 7.7% in today’s pre-market trading.
Doximity’s Segment Details
Doximity derives revenues from two sources: Subscription and Other.
In the first quarter of fiscal 2026, the Subscription revenues totaled $137.9 million, up 14.9% year over year. This was driven by the addition of new subscription customers and the expansion of existing customers. The expansion of existing customers was primarily driven by average revenue per existing Marketing Solutions customers increasing 14% as a result of adding new and growing existing brands and service lines.
The Other revenues totaled $8 million, up 19.8% year over year.
Doximity, Inc. Price, Consensus and EPS Surprise
Doximity, Inc. price-consensus-eps-surprise-chart | Doximity, Inc. Quote
DOCS’ Margin Trend
In the quarter under review, Doximity’s gross profit rose 15% year over year to $130.1 million. However, the gross margin contracted 13 basis points (bps) to 89.2%.
Sales and marketing expenses increased 3.2% year over year to $36.4 million, while research and development expenses increased 18.7% year over year to $26.8 million. General and administrative expenses increased 34.4% year over year to $12.4 million. Total operating expenses of $75.6 million rose 12.7% year over year.
The operating profit totaled $54.5 million, reflecting an 18.4% uptick from the prior-year quarter. The operating margin in the fiscal first quarter expanded 101 bps to 37.4%.
Doximity’s Financial Position
Doximity exited first-quarter fiscal 2026 with cash and cash equivalents of $137.3 million compared with $209.6 million at fiscal 2025-end.
Net cash provided by operating activities at the end of first-quarter fiscal 2026 was $62.1 million compared with $41.2 million a year ago.
DOCS’ Guidance
Doximity has provided its financial outlook for the second quarter of fiscal 2026 and upped its outlook for the full fiscal year.
For the fiscal second quarter, the company expects revenues in the range of $157 million-$158 million. The Zacks Consensus Estimate is pegged at $150.4 million.
DOCS now projects its full fiscal year revenues between $628 million and $636 million, up from the prior outlook of $619 million and $631 million. The Zacks Consensus Estimate is pegged at $625.7 million.
Our Take on Doximity
Doximity exited the first quarter of fiscal 2026 with better-than-expected results and solid top and bottom-line results. Robust performances by both its revenue sources were encouraging. The operating margin expansion also bodes well.
On the earnings call, management shared a few updates about its performance during the quarter. Per them, the unique active users on a quarterly, monthly and daily basis all grew in double-digit percentages year over year, while a record number of unique active prescribers used Doximity’s workflow tools to provide better care for their patients. The company also recently launched Doximity AI scribe. These look promising for the stock.
However, the gross margin contraction during the quarter was disappointing.
DOCS’ Zacks Rank and Key Picks
Doximity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. (GEHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.